Walleye Capital LLC Has $724,000 Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Walleye Capital LLC trimmed its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDAGet Rating) by 41.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 64,050 shares of the biopharmaceutical company’s stock after selling 44,441 shares during the quarter. Walleye Capital LLC’s holdings in Vanda Pharmaceuticals were worth $724,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in VNDA. Nisa Investment Advisors LLC lifted its stake in shares of Vanda Pharmaceuticals by 134.6% in the 1st quarter. Nisa Investment Advisors LLC now owns 8,540 shares of the biopharmaceutical company’s stock valued at $97,000 after purchasing an additional 4,900 shares during the period. CI Investments Inc. acquired a new position in shares of Vanda Pharmaceuticals in the 1st quarter valued at about $107,000. Wedge Capital Management L L P NC bought a new stake in Vanda Pharmaceuticals in the 1st quarter valued at about $117,000. Campbell & CO Investment Adviser LLC bought a new stake in Vanda Pharmaceuticals in the 1st quarter valued at about $119,000. Finally, Hsbc Holdings PLC bought a new stake in Vanda Pharmaceuticals in the 1st quarter valued at about $153,000. 99.42% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Price Performance

Shares of Vanda Pharmaceuticals stock opened at $9.94 on Wednesday. Vanda Pharmaceuticals Inc. has a one year low of $9.24 and a one year high of $21.44. The firm has a market capitalization of $562.22 million, a price-to-earnings ratio of 49.70 and a beta of 0.47. The business has a 50-day simple moving average of $10.56 and a 200 day simple moving average of $10.65.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 3rd.

Insider Activity at Vanda Pharmaceuticals

In other Vanda Pharmaceuticals news, CMO Joakim Wijkstrom sold 3,605 shares of the business’s stock in a transaction that occurred on Monday, August 22nd. The stock was sold at an average price of $10.27, for a total transaction of $37,023.35. Following the completion of the sale, the chief marketing officer now directly owns 96,673 shares of the company’s stock, valued at approximately $992,831.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.00% of the stock is currently owned by corporate insiders.

About Vanda Pharmaceuticals

(Get Rating)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Featured Articles

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDAGet Rating).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.